Published in J Infect Dis on August 07, 2001
Escalating Monthly Doses of Tafenoquine in Healthy Volunteers (TQ) | NCT05203744
Malaria: progress, perils, and prospects for eradication. J Clin Invest (2008) 6.54
Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science (2002) 6.19
Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother (2004) 4.54
Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol (2009) 3.84
History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev (2004) 3.40
Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine. Proc Natl Acad Sci U S A (2009) 2.54
Simple in vitro assay for determining the sensitivity of Plasmodium vivax isolates from fresh human blood to antimalarials in areas where P. vivax is endemic. Antimicrob Agents Chemother (2003) 2.26
Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci (2006) 2.09
A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J (2005) 2.09
pfcrt polymorphism and chloroquine resistance in Plasmodium falciparum strains isolated in Cambodia. Antimicrob Agents Chemother (2003) 1.89
Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob Agents Chemother (2008) 1.86
Role of cytochrome P450s in insecticide resistance: impact on the control of mosquito-borne diseases and use of insecticides on Earth. Philos Trans R Soc Lond B Biol Sci (2013) 1.74
In vitro sensitivity of Plasmodium falciparum from China-Myanmar border area to major ACT drugs and polymorphisms in potential target genes. PLoS One (2012) 1.74
Identification of a mutant PfCRT-mediated chloroquine tolerance phenotype in Plasmodium falciparum. PLoS Pathog (2010) 1.71
Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr Opin Infect Dis (2011) 1.68
pfcrt Allelic types with two novel amino acid mutations in chloroquine-resistant Plasmodium falciparum isolates from the Philippines. Antimicrob Agents Chemother (2003) 1.59
Recent highlights in antimalarial drug resistance and chemotherapy research. Trends Parasitol (2008) 1.52
Advances in understanding the genetic basis of antimalarial drug resistance. Curr Opin Microbiol (2007) 1.50
In vitro evaluations of antimalarial drugs and their relevance to clinical outcomes. Int J Parasitol (2008) 1.45
Chloroquine susceptibility and reversibility in a Plasmodium falciparum genetic cross. Mol Microbiol (2010) 1.42
World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. Malar J (2007) 1.41
Randomised trial of chloroquine/sulphadoxine-pyrimethamine in Gambian children with malaria: impact against multidrug-resistant P. falciparum. PLoS Clin Trials (2006) 1.39
Border malaria associated with multidrug resistance on Thailand-Myanmar and Thailand-Cambodia borders: transmission dynamic, vulnerability, and surveillance. Biomed Res Int (2013) 1.37
pfmdr1 amplification and fixation of pfcrt chloroquine resistance alleles in Plasmodium falciparum in Venezuela. Antimicrob Agents Chemother (2010) 1.36
Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs. PLoS Negl Trop Dis (2012) 1.36
Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria. Proc Biol Sci (2010) 1.31
Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials (2007) 1.28
Optimization of xanthones for antimalarial activity: the 3,6-bis-omega-diethylaminoalkoxyxanthone series. Antimicrob Agents Chemother (2002) 1.27
The rationale and plan for creating a World Antimalarial Resistance Network (WARN). Malar J (2007) 1.25
Novel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system. Antimicrob Agents Chemother (2005) 1.24
Clinically immune hosts as a refuge for drug-sensitive malaria parasites. Malar J (2008) 1.23
Origin and dissemination of chloroquine-resistant Plasmodium falciparum with mutant pfcrt alleles in the Philippines. Antimicrob Agents Chemother (2005) 1.21
Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol (2004) 1.19
Antimalarial drug resistance: a review of the biology and strategies to delay emergence and spread. Int J Antimicrob Agents (2013) 1.19
Therapeutic efficacy of chloroquine for treatment of Plasmodium vivax malaria cases in Halaba district, South Ethiopia. Parasit Vectors (2011) 1.18
A non-radioactive DAPI-based high-throughput in vitro assay to assess Plasmodium falciparum responsiveness to antimalarials--increased sensitivity of P. falciparum to chloroquine in Senegal. Am J Trop Med Hyg (2010) 1.18
Seventy-five years of Resochin in the fight against malaria. Parasitol Res (2009) 1.17
Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors. Parasitol Res (2006) 1.17
Real-time PCR assay for rapid detection and analysis of PfCRT haplotypes of chloroquine-resistant Plasmodium falciparum isolates from India. J Clin Microbiol (2007) 1.15
Drug susceptibility and genetic evaluation of Plasmodium falciparum isolates obtained in four distinct geographical regions of Kenya. Antimicrob Agents Chemother (2004) 1.15
Molecular characterisation of drug-resistant Plasmodium falciparum from Thailand. Malar J (2002) 1.11
Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum. Malar J (2007) 1.10
Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. Nat Commun (2014) 1.09
Strain theory of malaria: the first 50 years. Adv Parasitol (2008) 1.09
Amplification of pfmdr1, pfcrt, pvmdr1, and K13 propeller polymorphisms associated with Plasmodium falciparum and Plasmodium vivax isolates from the China-Myanmar border. Antimicrob Agents Chemother (2015) 1.07
Multiple origins of resistance-conferring mutations in Plasmodium vivax dihydrofolate reductase. Malar J (2008) 1.07
Pharmacokinetics, pharmacodynamics, and allometric scaling of chloroquine in a murine malaria model. Antimicrob Agents Chemother (2011) 1.06
Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy. Clin Microbiol Rev (2004) 1.06
High prevalence of markers for sulfadoxine and pyrimethamine resistance in Plasmodium falciparum in the absence of drug pressure in the Ashanti region of Ghana. Antimicrob Agents Chemother (2005) 1.06
Molecular surveillance of drug resistance through imported isolates of Plasmodium falciparum in Europe. Malar J (2002) 1.04
Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax. J Clin Microbiol (2005) 1.04
Molecular epidemiology of drug-resistant malaria in western Kenya highlands. BMC Infect Dis (2008) 1.04
Malaria drug resistance: new observations and developments. Essays Biochem (2011) 1.03
A new model for hemoglobin ingestion and transport by the human malaria parasite Plasmodium falciparum. J Cell Sci (2008) 1.01
Monitoring, characterization and control of chronic, symptomatic malaria infections in rural Zambia through monthly household visits by paid community health workers. Malar J (2014) 1.01
Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania. Malar J (2007) 1.00
Drug resistance in eukaryotic microorganisms. Nat Microbiol (2016) 1.00
An analytical model for genetic hitchhiking in the evolution of antimalarial drug resistance. Theor Popul Biol (2010) 0.98
A molecular map of chloroquine resistance in Mali. FEMS Immunol Med Microbiol (2009) 0.97
Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother (2007) 0.96
Purified Plasmodium falciparum multi-drug resistance protein (PfMDR 1) binds a high affinity chloroquine analogue. Mol Biochem Parasitol (2010) 0.95
Trends in chloroquine resistance marker, Pfcrt-K76T mutation ten years after chloroquine withdrawal in Tanzania. Malar J (2013) 0.95
Malaria diagnostics in clinical trials. Am J Trop Med Hyg (2013) 0.95
Resistance to antimalarial drugs: molecular, pharmacologic, and clinical considerations. Pediatr Res (2009) 0.94
Plasmodium falciparum: differential selection of drug resistance alleles in contiguous urban and peri-urban areas of Brazzaville, Republic of Congo. PLoS One (2011) 0.92
Rapid evolution of fluoroquinolone-resistant Escherichia coli in Nigeria is temporally associated with fluoroquinolone use. BMC Infect Dis (2011) 0.92
Chloroquine-resistant isoforms of the Plasmodium falciparum chloroquine resistance transporter acidify lysosomal pH in HEK293 cells more than chloroquine-sensitive isoforms. Mol Biochem Parasitol (2006) 0.92
Large-scale survey for novel genotypes of Plasmodium falciparum chloroquine-resistance gene pfcrt. Malar J (2012) 0.91
Role of Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes on in vitro chloroquine resistance in isolates of Plasmodium falciparum from Thailand. Am J Trop Med Hyg (2011) 0.91
Falciparum malaria molecular drug resistance in the Democratic Republic of Congo: a systematic review. Malar J (2015) 0.90
Balancing drug resistance and growth rates via compensatory mutations in the Plasmodium falciparum chloroquine resistance transporter. Mol Microbiol (2015) 0.90
Copper pathways in Plasmodium falciparum infected erythrocytes indicate an efflux role for the copper P-ATPase. Biochem J (2004) 0.90
Therapeutic efficacy of chloroquine for the treatment of uncomplicated Plasmodium falciparum in Haiti after many decades of its use. Am J Trop Med Hyg (2015) 0.90
Susceptibility of Anopheles gambiae and Anopheles stephensi to tropical isolates of Plasmodium falciparum. Malar J (2007) 0.90
Degrees of chloroquine resistance in Plasmodium - is the redox system involved? Int J Parasitol Drugs Drug Resist (2012) 0.89
Molecular markers of anti-malarial drug resistance in Lahj Governorate, Yemen: baseline data and implications. Malar J (2011) 0.89
Rapid identification of chloroquine and atovaquone drug resistance in Plasmodium falciparum using high-resolution melt polymerase chain reaction. Malar J (2010) 0.89
Frequency distribution of antimalarial drug resistance alleles among Plasmodium falciparum isolates from Gezira State, central Sudan, and Gedarif State, eastern Sudan. Am J Trop Med Hyg (2010) 0.89
Molecular surveillance as monitoring tool for drug-resistant Plasmodium falciparum in Suriname. Am J Trop Med Hyg (2013) 0.89
The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs. Int J Parasitol Drugs Drug Resist (2015) 0.88
Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials. J Med Chem (2012) 0.88
Usefulness of the recombinant liver stage antigen-3 for an early serodiagnosis of Plasmodium falciparum infection. Korean J Parasitol (2006) 0.88
Synthesis and structure-activity relationships of antimalarial 4-oxo-3-carboxyl quinolones. Bioorg Med Chem (2010) 0.87
High frequency of PfCRT 76T in two Malian villages and its prevalence in severe relative to non-severe malaria. Acta Trop (2011) 0.87
On the mechanism of chloroquine resistance in Plasmodium falciparum. PLoS One (2010) 0.87
Seasonal distribution of anti-malarial drug resistance alleles on the island of Sumba, Indonesia. Malar J (2009) 0.86
No genetic bottleneck in Plasmodium falciparum wild-type Pfcrt alleles reemerging in Hainan Island, China, following high-level chloroquine resistance. Antimicrob Agents Chemother (2007) 0.86
Use of a locked-nucleic-acid oligomer in the clamped-probe assay for detection of a minority Pfcrt K76T mutant population of Plasmodium falciparum. J Clin Microbiol (2005) 0.86
Lack of association between putative transporter gene polymorphisms in Plasmodium falciparum and chloroquine resistance in imported malaria isolates from Africa. Malar J (2006) 0.86
Polymorphism in plasmodium falciparum drug transporter proteins and reversal of in vitro chloroquine resistance by a 9,10-dihydroethanoanthracene derivative. Antimicrob Agents Chemother (2004) 0.86
Chloroquine sensitivity: diminished prevalence of chloroquine-resistant gene marker pfcrt-76 13 years after cessation of chloroquine use in Msambweni, Kenya. Malar J (2015) 0.86
Genetic Analysis and Species Specific Amplification of the Artemisinin Resistance-Associated Kelch Propeller Domain in P. falciparum and P. vivax. PLoS One (2015) 0.86
Literacy and recent history of diarrhoea are predictive of Plasmodium falciparum parasitaemia in Kenyan adults. Malar J (2006) 0.86
Sulfadoxine/pyrimethamine intermittent preventive treatment for malaria during pregnancy. Emerg Infect Dis (2010) 0.86
Uncertainty in mapping malaria epidemiology: implications for control. Epidemiol Rev (2010) 0.85
To kill or not to kill, that is the question: cytocidal antimalarial drug resistance. Trends Parasitol (2014) 0.85
Dihydroethanoanthracene derivatives as in vitro malarial chloroquine resistance reversal agents. Antimicrob Agents Chemother (2004) 0.85
Detection by real-time PCR of the Pfcrt T76 mutation, a molecular marker of chloroquine-resistant Plasmodium falciparum strains. Parasitol Res (2004) 0.84
A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med (2001) 9.18
Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity. Science (2011) 4.72
Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol (2001) 3.84
Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet (2001) 3.30
Molecular assays for surveillance of antifolate-resistant malaria. Lancet (1998) 2.26
Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol (2009) 2.17
Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications. Science (1987) 2.11
Hemoglobin C associated with protection from severe malaria in the Dogon of Mali, a West African population with a low prevalence of hemoglobin S. Blood (2000) 2.10
The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today (1997) 2.07
Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens (2004) 1.86
Application of a molecular marker for surveillance of chloroquine-resistant falciparum malaria. Lancet (2001) 1.85
Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance. Clin Pharmacol Ther (2007) 1.55
Antifolate resistance due to new and known Plasmodium falciparum dihydrofolate reductase mutations expressed in yeast. Mol Biochem Parasitol (1998) 1.44
Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet (2002) 1.36
Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain. Antimicrob Agents Chemother (1998) 1.34
Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. Am J Trop Med Hyg (1999) 1.28
Rapid selection of Plasmodium falciparum dihydrofolate reductase mutants by pyrimethamine prophylaxis. J Infect Dis (2000) 1.16
Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase of isolates from the Amazon region of Brazil. Mem Inst Oswaldo Cruz (2000) 1.12
Use of antimalarial drugs in Mali: policy versus reality. Am J Trop Med Hyg (1998) 1.10
More on 'the efficacy of antifolate antimalarial combinations in Africa'. Parasitol Today (1999) 1.10
Unidirectional dominance of cytoplasmic inheritance in two genetic crosses of Plasmodium falciparum. Mol Cell Biol (1993) 1.09
Erythrocyte CR1 expression level does not correlate with a HindIII restriction fragment length polymorphism in Africans; implications for studies on malaria susceptibility. Genes Immun (2002) 1.05
Identification of the Kna/Knb polymorphism and a method for Knops genotyping. Transfusion (2004) 0.99
A single dose of live oral cholera vaccine CVD 103-HgR is safe and immunogenic in HIV-infected and HIV-noninfected adults in Mali. Bull World Health Organ (1998) 0.99
A bifunctional dihydrofolate synthetase--folylpolyglutamate synthetase in Plasmodium falciparum identified by functional complementation in yeast and bacteria. Mol Biochem Parasitol (2001) 0.98
Conservation of a novel vacuolar transporter in Plasmodium species and its central role in chloroquine resistance of P. falciparum. Curr Opin Microbiol (2001) 0.95
Association of HLA alleles with Plasmodium falciparum severity in Malian children. Tissue Antigens (2011) 0.84
[In vitro cultivation of fields isolates of Plasmodium falciparum in Mali]. Bull Soc Pathol Exot (2007) 0.77